A Comparative Study of CEE, Tibolone, and DHEA as Hormone Replacement Therapy for Surgical Menopause
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The objective of this study was to compare the efficacy and safety of CEE, tibolone, and DHEA for prevention of menopausal symptoms.
One hundred patients with surgical menopause were included in this study: 25 of whom were not treated with any HRT, 25 were treated with 0.625 mg of CEE, 25 were treated with 2.5 mg of tibolone, and 25 were treated with 25 mg of DHEA for 1 year, and the results were statistically analyzed regarding drug efficacy and side effects at follow-up periods of 1, 6 and 12 months.
Frequency of menopausal symptoms was significantly less in cases received with CEE, tibolone, DHEA with p values 0.001, 0.004 and 0.004, respectively. Percentage gain in BMD was 2.8 % with CEE at lumbar spine, which was greater than that caused by DHEA and tibolone, but this difference was not statistically significant. CEE caused side effects like headache (40 %) and nausea (28 %).
CEE, Tibolone, and DHEA are very effective in alleviating climacteric symptoms. CEE has beneficial effects on lipid and bone and is a low-cost drug but frequently causes side effects. Tibolone offers beneficial androgenic effects on mood and libido with fewer side effects but is a costly drug. DHEA shows positive effects on psychological symptoms. However, its cost and androgenic side effects limit its use as long-term HRT.
- WHO Scientific Group. Research on the menopause. Tech Rep Ser. 1981;670:15–16.
- Kokcu, A, Cetinkya, MG, Yanik, F, Alper, T, Malatyalioglu, E (2000) The comparison of effects of tibolone and conjugated equine estrogen medroxyprogesterone acetate therapy on sexual performance in post menopausal women. Maturitas. 36: pp. 75-80 CrossRef
- Davis, SR (2002) The effects of tibolone on mood and libido. Menopause 9: pp. 162-170 CrossRef
- Arlt, W, Callis, F, Vlijmen, JC (1999) Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 341: pp. 1013-1020 CrossRef
- Alexendersen, P, Byrjalsen, I, Christiansen, C (2000) Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: effects on bone mass, lipoprotein metabolism, climacteric symptoms and adverse effects. Br J Obstet Gynaecol. 107: pp. 356-364 CrossRef
- Gallagher, J, Baylink, DJ, Me clung, M (2001) Prevention of bone loss with tibolone in postmenopausal women: results of two randomised, double blind, placebo-controlled, dose-findings studies. J Clin Endocrinol Metab. 86: pp. 4717-4726 CrossRef
- Egarter, C, Sator, M, Berghammer, P, Huber, J (1999) Efficacy, tolerability and rare side effects of tibolone treatment in postmenopausal women. Int J Gynaecol Obstet. 64: pp. 281-286 CrossRef
- Morales, AJ, Aubrich, RH, Hwang, JY (1994) The effects of six months treatment with a 100 mg daily dose of DHEA on circulating sex steroids, body composition and muscle strength in age-advanced men & women. Clin Endocrinol. 49: pp. 421-432 CrossRef
- A Comparative Study of CEE, Tibolone, and DHEA as Hormone Replacement Therapy for Surgical Menopause
The Journal of Obstetrics and Gynecology of India
Volume 63, Issue 3 , pp 194-198
- Cover Date
- Print ISSN
- Online ISSN
- Springer India
- Additional Links